October 26, 2020
Article
The company is planning to move forward after receiving a recommendation from the DSMB to start up the trial again.
Video
A case study examines a treatment for a hospitalized case of the virus.
Autoantibodies that attack type 1 interferons, neutralizing the immune system’s ability to block the SARS-CoV-2 virus, were present in 10% of patients with life-threatening coronavirus diseases 2019 (COVID-19) pneumonia, a new study found.
October 25, 2020
New data may evidence oral care as a therapeutic measure to reduce bacterial and viral spread.
October 24, 2020
The hospital found just 2 cases in their first 12 weeks were borne in the facility. A study author provides insight.
An investigator shares detail into how the neutralizing, immune-signaling molecule may provide continued success against the virus.
October 23, 2020
Ravina Kullar, PharmD, MPH, reflects on rapid advances in COVID-19 treatment understanding during IDWeek 2020.
New data show the pandemic, and a lack of efficacious therapies, did harm to 4 years' worth of stewardship.
The conclusion to the independent safety review punctuates a 50-day period of scrutiny and discussion around 2 non-fatal adverse events reported in patients.
Its phase 3 COVE trial enrollment is complete and the company is working towards its goal of FDA approval.
